Ensysce Biosciences Inc.

NASDAQ: ENSC · Real-Time Price · USD
2.10
0.04 (1.94%)
At close: Aug 15, 2025, 3:06 PM

Ensysce Biosciences Balance Sheet Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Cash & Equivalents
3.5M 1.12M 3.15M 12.26M
Short-Term Investments
n/a n/a n/a n/a
Long-Term Investments
n/a n/a n/a n/a
Other Long-Term Assets
252.55K 419.22K 558.72K -24.72B
Receivables
124.11K 97.56K 276.82K 441.72K
Inventory
n/a n/a -276.82K -441.72K
Other Current Assets
18K 18K 1.6M 2.59M
Total Current Assets
5.34M 2.29M 5.3M 15.66M
Property-Plant & Equipment
n/a n/a 27.16K 24.72B
Goodwill & Intangibles
n/a n/a n/a n/a
Total Long-Term Assets
252.55K 419.22K 585.88K 754.76K
Total Assets
5.6M 2.71M 5.89M 16.42M
Account Payables
1.36M 1.94M 2.94M 301.1K
Deferred Revenue
n/a n/a n/a n/a
Short-Term Debt
301.66K 854.7K 4.27M 12.75M
Other Current Liabilities
n/a n/a n/a n/a
Total Current Liabilities
2.21M 3.33M 9.46M 16.48M
Long-Term Debt
n/a n/a 140.15K 4.44M
Other Long-Term Liabilities
10.1K 26.39K 310.35K 3.65M
Total Long-Term Liabilities
10.1K 26.39K 450.49K 8.09M
Total Liabilities
2.22M 3.36M 9.91M 24.58M
Total Debt
301.66K 854.7K 4.43M 17.21M
Common Stock
136.00 315.00 53.00 124.00
Retained Earnings
-129,544.3B -121.56M -110.93M -85.85M
Comprehensive Income
n/a n/a n/a n/a
Shareholders Equity
3.71M -322.86K -4.03M -8.16M
Total Investments
3,502.1B n/a n/a n/a